Form 4 for DMAC DiaMedica Therapeutics Inc.
Accepted 2026-08-12 16:23:41 ET · period of report 2026-08-10 · accession 0001760123-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 16:23 | 2026-08-10 | DMAC | Pauls Dietrich John | Pres, CEO, Dir | A - Grant | $0.00 | +60.2K | 128.8K | +88% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Shares, no par value per share | 2026-08-10 | A | A | 60,200 | $0.00 | 128,791 | D | — | — | (F1) The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date. (F2) Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. |